Compare AbbVie Inc (ABBV) vs AST SpaceMobile Inc (ASTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs AST SpaceMobile Inc — how do they compare? AbbVie Inc trades at $252.69 (market cap $449.91B), while AST SpaceMobile Inc trades at $75.23 (market cap $22.17B). The key difference: AbbVie Inc is far larger — about 20.3× AST SpaceMobile Inc's market cap, and AbbVie Inc pays a 2.72% dividend while AST SpaceMobile Inc pays none. Which is the better fit depends on your goals.
| ABBV | ASTS | |
|---|---|---|
Market Cap | $449.91B | $22.17B |
Sector | Health | Media |
52-Week High | $261.07 | $133.09 |
52-Week Low | $184.85 | $36.91 |
Enterprise Value | $513.38B | $22.13B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
AST SpaceMobile (ASTS) trades at $74.21, down 12.83% in the last session amid a broader space stock selloff. The stock shows bearish technical signals with negative earnings surprises and deeply negative profitability margins. Recent news highlights satellite launch progress and competitive pressures from SpaceX, while cash flow remains heavily dependent on financing activities to fund operations and capital expenditures.
Outlook remains speculative with high execution risk; revenue growth is overshadowed by persistent losses and cash burn. Analyst consensus is mixed with a $84 price target offering potential upside, but investors face significant dilution risk and competitive threats in the nascent satellite broadband market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →
